Rituxim is a CD20-directed cytolytic antibody indicated for the treatment of patients with: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies. Initial dose for NHL and CLL is 375 mg/m2 in first cycle. Rituxim vials 100 mg and 500 mg are stable at 2°C−8°C & solutions for infusion may be stored at 2°C−8°C (36°F−46°F) for 24 hours. 


Product Name Rituxim
Generic Name Rituximab
Therapeutic Class Monoclonal Antibody (Mab)
Formulation Concentrated solution for infusion
Available Pack Size 1x1's
Available Strength 500 mg and 100 mg
Download Prescribing Information Visit Website